Previous 10 | Next 10 |
Preclinical data support the continued clinical development of NYX-783 as a novel mechanistic approach for treating post-traumatic stress disorder (PTSD) NYX-783 is currently under evaluation in a Phase 2b study in patients with PTSD Aptinyx Inc. (Nasdaq: APTX), a cl...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Gainers: Momentus (MNTS) +49%. Trevi Therapeutics (TRVI) +49%. Sunshine Biopharma (SBFM) +34%. Werewolf Therapeutics (HOWL) +30%. System1 (SST) +27%. AppTech Payments (APCX) +22%. MiNK Therapeutics (INKT) +21%. Ikena Oncology (IKNA) +19%. Sprinklr (CXM) +18%. PhaseBio Pharmaceuticals (PHAS) +...
Gainers: Trevi Therapeutics (TRVI) +36%. Sunshine Biopharma (SBFM) +31%. IMAC Holdings (IMAC) +28%. Werewolf Therapeutics (HOWL) +25%. Ikena Oncology (IKNA) +22%. Losers: Aptinyx (APTX) -47%. Vapotherm (VAPO) -29%. Rite Aid (RAD) -23%. Biophytis (BPTS) -13%. Science 37 Holdings (SNC...
The shares of clinical-stage biotech, Aptinyx (NASDAQ:APTX) have lost ~53% in the pre-market Thursday after the company announced that its Phase 2b clinical study for NYX-2925 did not reach the primary endpoint in patients with painful diabetic peripheral neuropathy (DPN). The 229-p...
NYX-2925 did not achieve the primary endpoint of the study Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase 2b clinical st...
Shares of Aptinyx Inc. (NASDAQ:APTX) traded at a new 52-week high today of $32.10. Approximately 38 million shares have changed hands today, as compared to an average 30-day volume of 168,000 shares. Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, deve...
Image source: The Motley Fool. Aptinyx Inc. (NASDAQ: APTX) Q4 2021 Earnings Call Mar 23, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Aptinyx Inc. (APTX) Q4 2021 Earnings Call Transcript
Aptinyx, Inc. (APTX) Q4 2021 Earnings Conference Call March 23, 2022, 05:00 PM ET Company Participants Patrick Flavin - Senior Manager, Corporate Development and Investor Relations Andy Kidd - President & CEO Ashish Khanna - CFO & Chief Business Officer Conference Call Participants Ch...
Aptinyx press release (NASDAQ:APTX): Q4 GAAP EPS of -$0.29 beats by $0.05. Cash and cash equivalents were $106.1 million at December 31, 2021. For further details see: Aptinyx GAAP EPS of -$0.29 beats by $0.05
News, Short Squeeze, Breakout and More Instantly...
Signature Bank (SBNY) is expected to report for Q3 2023 BHP Group Ltd. (BHP) is expected to report for Q1 2024 Sorrento Therapeutics Inc. (SRNEQ) is expected to report $-0.15 for Q3 2023 Baran Group Ltd. (BRANF) is expected to report for quarter end 2023-09-30 World Copper (WCUFF)...
GLG Life Tech Corporation (GLGLF) is expected to report for Q1 2024 Accenture plc Class A (Ireland) (ACN) is expected to report $3.14 for Q1 2024 Greenlane Holdings Inc. (GNLN) is expected to report $-2.7 for Q3 2023 iMedia Brands Inc. (IMBIQ) is expected to report for quarter end 202...
Axcella Health Inc. (AXLA) is expected to report for Q3 2023 Telekom Malaysia Bhd (MYTEF) is expected to report for quarter end 2023-09-30 Atento S.A. (ATTOF) is expected to report for Q3 2023 Scryb Inc Com (SCYRF) is expected to report for Q4 2023 BHP Group Ltd. (BHP) is expected...